较高剂量西格列汀与老年CKD患者充血性心力衰竭风险
本研究为基于人群的队列研究,纳入2010-2017年加拿大安大略省>66岁、eGFR<45 ml/min/1.73 m2且未透析的2型糖尿病新使用西格列汀患者,比较>50 mg/d与≤50 mg/d组1年内死亡或充血性心力衰竭住院风险。结果显示两组主要复合终点无显著差异,高剂量组HbA1c略低且全因住院风险较低。
要点
- 老年CKD患者使用西格列汀>50 mg/d不增加死亡或心衰住院风险。
- 高剂量组全因住院风险较低(加权HR 0.81)。
- 高剂量组HbA1c略低(加权组间差-0.12%)。
核心结论
- 在老年CKD患者中,起始西格列汀>50 mg/d相比≤50 mg/d未增加1年死亡或充血性心力衰竭住院风险。
研究设计与样本
- 基于人群的队列研究,纳入9215例>66岁、eGFR<45 ml/min/1.73 m2且未透析的2型糖尿病新使用西格列汀患者。
- 使用倾向评分逆概率治疗加权平衡基线特征,比较>50 mg/d组(6518例)与≤50 mg/d组(2697例)。
主要发现
- 主要复合终点(死亡或充血性心力衰竭住院)1年风险两组无显著差异(79 vs 126事件/1000人年;加权HR 0.88;95%CI 0.67-1.14)。
- 胰腺炎住院(加权HR 0.98;95%CI 0.32-3.03)和低血糖住院(加权HR 1.10;95%CI 0.64-1.90)风险无显著差异。
- 高剂量组平均糖化血红蛋白较低(加权组间差-0.12%;95%CI -0.19至-0.06),全因住院风险较低(加权HR 0.81;95%CI 0.66-0.98)。
临床怎么用
- 对于eGFR<45 ml/min/1.73 m2的老年2型糖尿病患者,临床可考虑使用西格列汀>50 mg/d而不必担忧增加心衰风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is commonly prescribed to patients with type 2 diabetes. As this drug is primarily eliminated by the kidney, a reduced dose is recommended for patients with CKD. Some evidence suggests that sitagliptin is associated with a higher risk of congestive heart failure, particularly at higher doses. We compare the 1-year risk of death or hospitalization with congestive heart failure in patients with CKD newly prescribed sitagliptin at >50 versus ≤50 mg/d. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This population-based cohort study included older adults (>66 years) with type 2 diabetes and an eGFR<45 ml/min per 1.73 m2 (but not receiving dialysis) who were newly prescribed sitagliptin between 2010 and 2017 in Ontario, Canada. We used inverse probability of treatment weighting on the basis of propensity scores to balance baseline characteristics. The primary composite outcome was death or hospitalization with congestive heart failure. Secondary outcomes included hospitalization with pancreatitis or hypoglycemia, all-cause hospitalization, and glycemic control. Weighted hazard ratios were obtained using Cox proportional hazards regression, and 95% confidence intervals were obtained using bootstrap variance estimators. RESULTS: Of 9215 patients, 6518 started sitagliptin at >50 mg/d, and 2697 started sitagliptin at ≤50 mg/d. The 1-year risk of death or hospitalization with congestive heart failure did not differ significantly between groups (79 versus 126 events per 1000 person-years; weighted hazard ratio, 0.88; 95% confidence interval, 0.67 to 1.14); hospitalization with pancreatitis (weighted hazard ratio, 0.98; 95% confidence interval, 0.32 to 3.03) and hypoglycemia (weighted hazard ratio, 1.10; 95% confidence interval, 0.64 to 1.90) also did not differ significantly between groups. Patients starting sitagliptin at >50 mg/d had lower mean glycated hemoglobin concentrations (weighted between-group difference, -0.12%; 95% confidence interval, -0.19 to -0.06) and a lower risk of all-cause hospitalization (weighted hazard ratio, 0.81; 95% confidence interval, 0.66 to 0.98). CONCLUSIONS: The risk of death or congestive heart failure was not higher in older adults with CKD starting sitagliptin at >50 versus ≤50 mg/d. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_11_25_CJN08310520_final.mp3.
引用
- Muanda FT, Weir MA, Bathini L, et al. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. Clin J Am Soc Nephrol. 2020. PMID: 33239410. doi:10.2215/CJN.08310520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。